Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Slides:

Advertisements

Similar presentations

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Weng TC, et al. J Clin Pharm Ther 2010;35:

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.

Philip J. Barter, et al. Circulation 2011;124:

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階カンファレンス室.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

From: High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)

Baseline Characteristics of the Patients Part I

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Arterioscler Thromb Vasc Biol

Oxford Niacin Trial.

TNT: Baseline and final LDL cholesterol levels

Behavior and Biology: The Basic Sciences for AHA Action

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Effect of evolocumab on lipoprotein particles

TNT Study: Baseline Characteristics of the Patients

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

PREMIER: Rate of hypertension at 18 months

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Subject Characteristics

Hajer GR et al. Atherosclerosis 2009;202:216-24

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Plus–minus values are means ±SE

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Flow of Patients Through the Trial

Study Participant Flow

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Baseline Characteristics of the Patients – Part I

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Potential Mechanisms of Adverse Outcomes Associated with Torcetrapib

RECORD Study: Enrollment and Outcomes

Characteristics of included studies

RADIANCE 2 Study: Trial proﬁle

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

The ACCORD Study Group. NEJM 2010; Epub March 14

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Change in markers of glycometabolism and cardiovascular risk profile.

Flow of study participants

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part II John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Changes in Levels of High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) Cholesterol in Patients Receiving Atorvastatin Alone or Atorvastatin plus Torcetrapib John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Changes in Lipoprotein Subclasses* John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Baseline, Follow-up, and Change from Baseline in End Points for Maximum Carotid Intima-Media Thickness* John J.P. Kastelein, et al. N Engl J Med 2007;356: online

Average Maximum Carotid Intima-Media Thickness during 24 Months of Treatment John J.P. Kastelein, et al. N Engl J Med 2007;356: online